A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-09-12
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, dose escalation, and expansion human clinical study to
observe the safety, tolerability, pharmacokinetics, and pharmacodynamics of XZP-3621 in
single and multiple oral administrations in advanced NSCLC subjects with ALK rearrangement or
ROS1 rearrangement, and to initially explore the efficacy of XZP-3621.The study was divided
into two parts: dose escalation and dose expansion.